Sort
85,873 grants matching “alzheimers”
Scale-up and Synthesis of a Tau Oligomer Inhibitor to initiate IND enabling studies for AD and ADRD
$999,937James G. Moe · Oligomerix, Inc · R44 · FY2020 · AG
Multi-site longitudinal Integrated Neurocognitive and Sleep-Behavior Profiler for the Endophenotypic Classification of Dementia Subtypes (INSPECDS)
$999,922Chris Berka · Advanced Brain Monitoring, Inc. · R44 · FY2022 · AG
Pre-clinical development of NGP 555 for the prevention of AD
$999,911William T Comer · Neurogenetic Pharmaceuticals, Inc. · U44 · FY2013 · NS
Personalized, Easy-To-Use Tool for AD/ADRD Caregivers Addressing Financial Management and Legal Planning
$999,869Kevin M. Kramer · Minnesota Healthsolutions Corporation · R44 · FY2022 · AG
SBIR Phase II: Flexible Thin-Film Thermoelectric Wearable Energy Harvester
$999,834Marcus Ward · Perpetua Power Source Technologies, Inc. · · FY2011 · TIP
Genetic Epidemiology of Alzheimer's Disease in Hispanics
$999,800Richard Mayeux · Columbia University Health Sciences · R37 · FY2013 · AG
Development of a novel Alzheimer's disease therapeutic targeting tau
$999,721Glenn Larsen · Aquinnah Pharmaceuticals, Inc. · R44 · FY2024 · AG
Pre-clinical development of NGP 555 for the prevention of AD
$999,681William T Comer · Neurogenetic Pharmaceuticals, Inc. · U44 · FY2012 · NS
Pharmacology of Stimulus Memory and Habit Formation
$999,652Mortimer Mishkin · National Institute Of Mental Health · ZIA · FY2015 · MH
A Single-cell Platform for Analyzing the Peripheral Immune Response in Alzheimerâs and Alzheimerâs Related Diseases
$999,615Timothy S McConnell · Isoplexis, Inc. · R44 · FY2020 · AG
SBIR Phase II: Ecosystem Design Tool
$999,592Daniel Fleischer · Hyphae Design Lab · · FY2023 · TIP
Personalized, Easy-To-Use Tool for AD/ADRD Caregivers Addressing Financial Management and Legal Planning
$999,587Kevin M. Kramer · Minnesota Healthsolutions Corporation · R44 · FY2023 · AG
Down Syndrome Connect Registry
$999,558Joaquin M. Espinosa · University Of Colorado Denver · OT2 · FY2025 · HD
Elemental And Structural Organization Of Neurons And Glia
$999,512S Brian Andrews · National Institute Of Neurological Disorders And Stroke · ZIA · FY2012 · NS
Recharge Behavioral Therapy for caregivers of individuals with Alzheimer's Disease
$999,503Bruno Kajiyama · Photozig, Inc. · R44 · FY2024 · AG
Pre-clinical development of NGP 555 for the prevention of AD
$999,249William T Comer · Neurogenetic Pharmaceuticals, Inc. · U44 · FY2014 · NS
Tau oligomer platform validation using lead series candidate in htau mice
$999,248James G. Moe · Oligomerix, Inc · R44 · FY2018 · AG
Neuropeptides and Carboxypeptidase E/ Neurotrophic Factor-1 in Neural and Cognitive Functions
$999,238Yoke Peng Loh · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2017 · HD
Racial Differences in Late-Life Cognitive Decline and Risk of Alzheimer's Disease
$998,952Lisa L Barnes · Rush University Medical Center · RF1 · FY2018 · AG
Genetic Architecture of Pure Alzheimer's Disease and Mixed Pathology
$998,897Shubhabrata Mukherjee · University Of Washington · R01 · FY2024 · AG
Optimization and Validation of an Indicator Cell Assay for Blood-Based Diagnosis of Alzheimer's Disease
$998,853Jennifer Joy Smith · Precyte, Inc. · R44 · FY2019 · AG
Optimization and Validation of an Indicator Cell Assay for Blood-Based Diagnosis of Alzheimer's Disease
$998,853Jennifer Joy Smith · Precyte, Inc. · R44 · FY2020 · AG
Research Centers Collaborative Network Renewal
$998,830Stephen B Kritchevsky · Wake Forest University Health Sciences · U24 · FY2023 · AG
Development of a novel Alzheimer's disease therapeutic targeting tau
$998,691Glenn Larsen · Aquinnah Pharmaceuticals, Inc. · R44 · FY2025 · AG
Clinical trials to prevent Alzheimer's Disease in Down Syndrome
$998,408Michael S Rafii · University Of Southern California · R61 · FY2020 · AG